SUTENT - SUTENT - CT 4512 - English version

Has

Description

Introduction SUTENT 12,5 mg, capsule Bottle of 30 (CIP: 376 265-0) SUTENT 25 mg, capsule Bottle of 30 (CIP: 376 266-7) SUTENT 50 mg, capsule Bottle of 30 (CIP: 376 267-3) Posted on Apr 24 2008 Active substance (DCI) Sunitinib ATC Code L01XE04 Laboratory / Manufacturer PFIZER SUTENT 12,5 mg, capsule Bottle of 30 (CIP: 376 265-0) SUTENT 25 mg, capsule Bottle of 30 (CIP: 376 266-7) SUTENT 50 mg, capsule Bottle of 30 (CIP: 376 267-3) Posted on Apr 24 2008

Sujets

• Cancer
• Médecine

Informations

• Publié par: haute-autorite-sante-cancers
• Publié le: 23 mai 2007
• Nombre de lectures: 16
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

 

 

 

  The legally binding text is the original French version   TRANSPARENCY COMMITTEE

Opinion

23 May 2007     SUTENT 12,5 mg, capsule Bottle of 30 (CIP: 376 265-0) SUTENT 25 mg, capsule Bottle of 30 (CIP: 376 266-7) SUTENT 50 mg, capsule Bottle of 30 (CIP: 376 267-3)   Applicant : PFIZER   Sunitinib   ATC Code: L01XE04   List I Medicinal product for hospital prescription only. Prescription restricted to oncology or haematology specialists or qualified cancer physicians. Medicine requiring specific monitoring during treatment     Date of Marketing Authorisation (centralised procedure): 19 July 2006 Marketing Authorisation Revision (new description of indication): 11 January 2007     Current management conditions: Included on the list of medicines reimbursed by National Insurance and for hospital use and various public services       Reason for request: Change in the description of the indication in the treatment of renal cell carcinoma                 Health Technology Assessment Division  

 

1